TIGIT and cancer: As summarized in Figure 2, therapy resistance in PDAC arises from multifaceted origins: tumor cells exploit the TIGIT signaling pathway to suppress CD8+ T cell function, thereby driving immunotherapy failure, while the IL-6/CAFs axis acts in concert with CD44+ cancer stem cells within the tumor microenvironment to induce chemotherapy resistance.